Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1 results about "Neovascularization" patented technology

Neovascularization is the natural formation of new blood vessels (neo- + vascular + -ization), usually in the form of functional microvascular networks, capable of perfusion by red blood cells, that form to serve as collateral circulation in response to local poor perfusion or ischemia. Neovascularization is conventionally distinguished from angiogenesis in that angiogenesis is mainly characterized by the protrusion and outgrowth of capillary buds and sprouts from pre-existing blood vessels. Vasculogenesis can be synonymous with neovascularization but also often has reference instead to prenatal development and the initial embryologic formation of blood vessels. Growth factors that inhibit neovascularization include those that affect endothelial cell division and differentiation. These growth factors often act in a paracrine or autocrine fashion; they include fibroblast growth factor, placental growth factor, insulin-like growth factor, hepatocyte growth factor, and platelet-derived endothelial growth factor.

Liver targeted peptide-recombinant human endostatin fusion protein, and preparation method and application thereof

ActiveCN103319606AStrong specificityImprove the dose-effect ratioBacteriaPeptide/protein ingredientsSide effectWhole body
The invention discloses a liver targeted peptide-recombinant human endostatin fusion protein, and a preparation method and application thereof. According to the invention, 19 amino acids in the N terminal conserved I region of plasmodium circumsporozoite protein (CSP) capable of being specifically combined with hepatocyte surface receptor--heparan sulfate proteoglycan (HSPG) are fused to the carboxyl terminal of a novel human endostatin (nhES), the amino terminal of which is added with 9 amino acid sequences (MGGSHHHHH), by a gene engineering method, thereby obtaining the liver targeted peptide-recombinant human endostatin fusion protein (ES-CPS). The fusion protein is easy to purify, can be specifically used in livers for inhibiting neovascularization in a targeted mode, enhances the local concentration of the medicine in the foci, reduces the consumption to the whole body, and lowers the toxic or side effect. The invention provides an idea and scientific reference for clinically developing medicines for treating liver cancers by targeted inhibition of neovascularization, and has huge scientific meanings and practical value for further enhancing the liver cancer treatment level in China.
Owner:GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products